Arctic Bioscience — AGM Information 2025

Oct 28, 2025

Arctic Bioscience - Notice of Extraordinary General Meeting on 11 November 2025

Arctic Bioscience - Notice of Extraordinary General Meeting on 11 November 2025

An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 11

November 2025 at 10:00 (CET), as a digital meeting.

The agenda of the meeting is election of a new auditor for the Company. The

elected auditor, PwC, has informed Arctic Bioscience AS of corporate

reorganization that will result in a portion of their business, including

partners, employees and clients, being moved to a wholly owned subsidiary.

Arctic Bioscience AS is one of the clients that has been moved to the wholly

owned subsidiary. The move does not entail any changes to the services provided.

The reorganization of PwC therefore only has the practical effect that PwC's

subsidiary, PwC Assurance AS, must be elected as auditor instead of PwC AS. See

notice for more information.

Shareholders are encouraged to cast their votes in advance of the General

Meeting or grant the Chair of the Board a proxy, with or without voting

instructions.

Deadline for registration of attendance, advance votes, proxy or instructions is

7 November 2025 at 16:00 (CET). For attendance to the live event, please follow

the instructions in the notice.

For further information, see the attached Notice of the Extraordinary General

Meeting, which can also be accessed from the company's website (https://arctic

-bioscience.com/investors/general-meetings/).

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.